NextCell Pharma Past Earnings Performance
Past criteria checks 0/6
NextCell Pharma's earnings have been declining at an average annual rate of -21.8%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 41% per year.
Key information
-21.8%
Earnings growth rate
2.9%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 41.0% |
| Return on equity | -70.5% |
| Net Margin | -257.2% |
| Next Earnings Update | 25 Jul 2024 |
Recent past performance updates
Recent updates
We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully
Mar 09
We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate
Oct 07NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans
May 23NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans
Feb 01We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth
Sep 21Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation
May 31We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully
Feb 15Revenue & Expenses BreakdownBeta
How NextCell Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 29 Feb 24 | 15 | -39 | 45 | 0 |
| 30 Nov 23 | 16 | -41 | 46 | 0 |
| 31 Aug 23 | 14 | -40 | 43 | 0 |
| 31 May 23 | 11 | -40 | 41 | 0 |
| 28 Feb 23 | 9 | -38 | 38 | 0 |
| 30 Nov 22 | 8 | -37 | 35 | 0 |
| 31 Aug 22 | 6 | -35 | 32 | 0 |
| 31 May 22 | 6 | -30 | 28 | 0 |
| 28 Feb 22 | 6 | -28 | 24 | 0 |
| 30 Nov 21 | 5 | -26 | 21 | 0 |
| 31 Aug 21 | 4 | -25 | 19 | 0 |
| 31 May 21 | 4 | -25 | 18 | 0 |
| 28 Feb 21 | 4 | -23 | 17 | 0 |
| 30 Nov 20 | 4 | -19 | 16 | 0 |
| 31 Aug 20 | 4 | -18 | 15 | 0 |
| 31 May 20 | 4 | -17 | 14 | 0 |
| 29 Feb 20 | 4 | -17 | 13 | 0 |
| 30 Nov 19 | 3 | -16 | 13 | 0 |
| 31 Aug 19 | 2 | -18 | 14 | 0 |
| 31 May 19 | 2 | -17 | 14 | 0 |
| 28 Feb 19 | 1 | -15 | 13 | 0 |
| 30 Nov 18 | 1 | -16 | 12 | 0 |
| 31 Aug 18 | 1 | -14 | 10 | 0 |
| 31 May 18 | 1 | -15 | 10 | 0 |
| 28 Feb 18 | 1 | -16 | 11 | 0 |
| 30 Nov 17 | 1 | -14 | 11 | 0 |
| 31 Aug 17 | 1 | -13 | 10 | 0 |
| 31 May 17 | 1 | -11 | 10 | 0 |
| 28 Feb 17 | 1 | -10 | 10 | 0 |
| 30 Nov 16 | 1 | -11 | 10 | 0 |
| 31 Aug 16 | 1 | -11 | 11 | 0 |
| 31 Aug 15 | 0 | -7 | 7 | 0 |
Quality Earnings: NXTCL is currently unprofitable.
Growing Profit Margin: NXTCL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NXTCL is unprofitable, and losses have increased over the past 5 years at a rate of 21.8% per year.
Accelerating Growth: Unable to compare NXTCL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NXTCL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: NXTCL has a negative Return on Equity (-70.51%), as it is currently unprofitable.